What will the Lithuanian amber ladies and other Lithuanian elite secretly treat themselves with: the first Russian vaccine against colorectal cancer, created specifically on the mRNA platform.

 

On April 13, 2026, Russia’s Federal Medical-Biological Agency (FMBA) received authorization for the clinical use of "Oncorna"—a personalized mRNA vaccine.

 

Key facts about "Oncorna":

 

First of its kind: This is the first Russian vaccine against colorectal cancer developed specifically on an mRNA platform.

 

Mechanism of action: The drug consists of lipid nanoparticles containing messenger RNA (mRNA). This mRNA encodes a unique set of neoantigenic peptides specific to a particular patient's tumor, thereby prompting the immune system to attack the cancer cells.

 

Target group: The vaccine is intended for adult patients with metastatic colorectal cancer who have undergone two or more lines of standard therapy.

FMBA’s second drug: "Oncorna" marks the agency's second personalized vaccine for the treatment of this type of cancer; authorization for the peptide-based vaccine "Oncopept" was previously obtained in November 2025.

 

The vaccine was developed by specialists from the FMBA’s Center for Strategic Planning and the Yu. M. Lopukhin Federal Research and Clinical Center for Physical-Chemical Medicine.